The Hepatitis B drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Hepatitis B virus (HBV) is a vaccine-preventable infection that can spread in healthcare setting, people who inject drugs, or through sexual transmission. The prevalence of HBV infection in Kenya is estimated to be between 1% to 5%, although rates among specific high-risk populations (HIV co-infected, drug abusers, jaundiced patients seeking medical care) are much higher. Due to similar routes of transmission, Human Immunodeficiency Virus (HIV) infected individuals are also at high risk for Hepatitis B infection.
Hepatitis B drug market is driven by the high prevalence of Hepatitis in Kenya. The risk of Hepatitis B infection is greatly increased due to the high prevalence of HIV/AIDs in Kenya as HIV and HBV share common modes of transmission.
Adolescents aged 15-24 years constitute major blood donors in Kenya. This population indulges in risk activities like unprotected sexual activities, injecting drugs with infected syringes, piercings and tattoos increasing the risk of exposure to HBV infection.
Increase in substance abuse, involving in unprotected sex and other risk factors among adolescents in Kenya are leading to high incidence of HBV infections.
Increase in Government initiatives like screening for hepatitis among high-risk populations and providing clinical care for patients who have tested positive is expected to fuel growth in the hepatitis drug market.
However, the side effects caused by several drug are restraining market growth. The outbreak of COVID-19 has decreased diagnosis, screening and follow-up of patients suffering from hepatitis which has negative outcomes of health in patients with hepatitis.